Dr. Andreadis Discusses FDA-Approved CAR T-Cell Therapies in DLBCL

Video

In Partnership With:

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

There are 2 approved products now—–tisagenlecleucel (Kymriah), which is a 4-IBB product and axicabtagene-ciloleucel (Axi-cel; Yescarta), which is a CD28 product. They have very similar activity, says Andreadis. To date, clinical trials have shown response rates in the 50% range and long-term responses in 30% to 40% of patients, adds Andreadis.

However, they have different toxicity profiles. The toxicity with tisagenlecleucel is mainly low-grade cytokine release syndrome (CRS). There is a little bit of neurological toxicity, though it does not often require secondary agent support. Axi-cel has more of a robust and early onset toxicity profile, says Andreadis. Physicians have noted higher rates of CRS and neurotoxicity, as well as higher use of tocilizumab and steroids, which may make it more challenging to give in the outpatient setting.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD